Patent · US Active

MDM2 inhibitor and a platinum compound for cancer treatment

US11850239B2 · kind B2 · utility

1Cited by

0References

20Claims

0Family size

Assignees

ASCENTAGE PHARMA (SUZHOU) CO., LTD. · CN
ASCENTAGE PHARMA GROUP CORP LIMITED · CN

Inventors

Yifan Zhai · Suzhou, CN
Dajun Yang · Suzhou, CN

Key dates

Filing date	Dec 18, 2020
Grant date	Dec 26, 2023
Priority date	—
Expiry date	Aug 28, 2041

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein is a method of treating, preventing, or alleviating one or more symptoms of a disorder, disease, or condition mediated by an MDM2 with an MDM2 inhibitor, e.g., a compound of Formula (I), and a platinum compound. Also provided herein is a method of inhibiting the growth of a cell with an MDM2 inhibitor and a platinum compound.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.